MEASLES

TRANSMISSION					
Source: Humans only Transmission: <u>Airborne</u> : by droplet spread <u>Direct contact</u> : with nasal or throat secretion <u>Fomites</u> : article freshly soiled with nasal or throat	Incubation Period 8-12 (7-21) days	Prodrome: 2-4 days Fever (103°F-105°F), cough, coryza, conjunctivitis, Koplik spots <u>Communicability</u> : -4 days through 4 days after rash onset		Eruptive phase: ~1 week Rash: begins on face and neck, maculopapular, becomes confluent Complication: Common: diarrhea, otitis media, pneumonia, bronchitis Less Common: encephalitis,	
secretion Attack rate: 90% Household = 95%		Children in school: rash HCW: rash onset + 4 da Exposed HCW: Exp + 5 d	onset + 4 days ys days to + 21 da	ys IgG detectable from rash to 1-2 months IgG detectable 7-10 days after rash and stays for the rest of life	
DIAGNOSIS					
Clinical Case Definition Illness characterized by:Laboratory Criteria for Diagnosis• generalized maculopapular rash lasting ≥3 days; and • temperature ≥ 101°F (38.3°C); and • cough, coryza, or conjunctivitis• Isolation of measles virus from a clinical specimen; or • Isolation of measles virus-specific nucleic acid using PCR; or • IgG seroconversion or a significant rise in measles IgG antibody; or • a positive serologic test for measles IgM antibody.					
<u>Confirmed</u> : Meets clinical case definition and laboratory criteria OR meets clinical case definition and is epidemiologically linked to a laboratory-confirmed case. <u>Probable</u> : Meets clinical case definition and has no measles-specific laboratory testing or epidemiologic linkage to a confirmed case.				Serologic testing is <u>not</u> a good diagnostic tool among immunized persons:	
<u>International Importation</u> : Onset of rash within 21 days of entering the US and no link to local transmission. <u>Indigenous Case</u> : Case that cannot proven to be imported. <u>Out-of-State Importation</u> : Out-of-state for exposure period or has an epidemiologic linkage to an out-of-state case.				 IgM may last long after immunization, or may be transient/not detected in true cases. 	
TREATMENT, PROPHYLAXIS					
Treatment: • Supportive • Vitamin A orally (200,000 IU for children ≥ 1 year of age, 100,000 IU for children 6-11 months old, and 50,000 IU for infants < 6 months old)Prophylaxis of the exposed: • Vaccination within 72 hours of exposure • Immunoglobulin within 6 days of exposure • Immunoglobulin within 6 days of exposure • Household contacts • Healthcare facility contacts • Institutional contacts (i.e. child care centers and schools)Routine Childhood Vaccine 2 doses of live attenuated vaccine (at least 1 month ap Recommended age: • 1st dose at 12-15 months • 2nd dose at 4-6 years.					
Airborne precautions		CONTROL			
 Report to OPH within 24 H Report to Immunization P Children should be kept or Strict segregation of child Asses vaccination status a Institutional outbreak: vac Healthcare facility: HCWs Measles no longer in timportation Confirm reports of ca < 5 days post rash 	nours. rogram ut of school for 4 days a ren if measles occurs in ind vaccinate exposed, s ccine or immunoglobulir in contact with cases sh the USA, cases linked ses ASAP: onset: PCR onset: PCR and serolog	fter rash appears an institution susceptible individuals to new admissions. nould be immunized.		Live vaccine within 72 hours, Immunoglobulin if live vaccine is Contraindicated: Children < 1-year age Pregnant women Immunocompromised persons	